Skip to main content

Table 4 Baseline characteristics of patients in each trial

From: Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis

Trial

Included VHD

Baseline Clinical Characteristics

Group

Age

CHADS2

HAS-BLED

HTN

CVA

DM

MI

ARISTOTLE*

Bioprosthetic valve

/

71 (64, 77)

2.2 ± 1.1

N/A

4102 (85.3)

905 (18.8)

1086 (22.6)

837 (17.4)

(Avezum et al., 2015)

Mitral valve repair

 

Native valve disease

ENGAGE AF-TIMI 48* (De Caterina et al., 2017)

Bioprosthetic valve

HDER

71.8 ± 9.4

2.92 ± 1.0

2.55 ± 0.98

2629 (93.1)

668 (23.7)

908 (32.2)

1122 (39.8)

Mitral valve repair

LDER

Native valve disease

 

RE-LY

Native valve disease

Intervention: D110

74 (68, 78)

2 (1,3)

N/A

988 (76.5)

279 (21.6)

298 (23.1)

251 (19.4)

(Ezekowitz et al., 2016)

Intervention: D150

74 (67, 79)

2 (1,3)

1051 (77.7)

310 (22.9)

320 (23.7)

250 (18.5)

 

Control

74 (68, 79)

2 (1,3)

N/A

1012 (77.5)

286 (21.9)

316 (24.2)

212 (16.2)

ROCKET AF*

Mitral valve repair

AS

78 (73, 82)

3.6 ± 0.9

3 ± 0.9

197 (92)

99 (46)

92 (43)

64 (30)

(Breithardt et al., 2016)

Native valve disease

MR/AR

74 (67, 79)

3.5 ± 1.0

2.8 ± 1.0

1542 (89)

829 (48)

690 (40)

404 (23)

Seeger et al.

Post-TAVI

/

81.3 ± 5.9

4.9 ± 1.2 (CHA2DS2VASc)

3.1 ± 1.1

N/A

35 (12.9)

32.4 (88)

19.5 (53)

−2017

(Geis et al., 2018)

Post-TAVI

Intervention

83.1 ± 5.3

4.6 ± 1.2 (CHA2DS2VASc)

2.7 ± 0.8

147 (95)

24 (16)

47 (31)

80 (52)

Control

83.0 ± 4.9

4.8 ± 1.3 (CHA2DS2VASc)

2.9 ± 0.8

158 (92)

25 (15)

57 (33)

88 (51)